Superworth

Fulcrum Therapeutics EPS FULC

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$1.21
Latest quarter, Q2 FY26
−$0.34
Fiscal year 2025
−$1.18

Fulcrum Therapeutics' earnings per share was −$1.21 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.34.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.18n/a
FY2024−$0.18n/a
FY2023−$1.58n/a
FY2022−$2.48n/a
FY2021−$2.29n/a
FY2020−$2.81n/a
FY2019−$35.18n/a
FY2018−$31.10n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.34n/a−$1.21
Q1 FY26−$0.25n/a−$1.15
Q4 FY25−$0.31n/a−$1.18
Q3 FY25−$0.31n/a−$1.14
Q2 FY25−$0.28−132%−$1.18
Q1 FY25−$0.28n/a−$0.03
Q4 FY24−$0.27n/a−$0.18
Q3 FY24−$0.35n/a−$0.31
Q2 FY24$0.87n/a−$0.35
Q1 FY24−$0.43n/a−$1.60
Q4 FY23−$0.40n/a−$1.58
Q3 FY23−$0.39n/a−$1.68

Against its peers

Companies in Drug Manufacturers - General nearest Fulcrum Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
FULCFulcrum Therapeutics−$1.21
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
AMPHAmphastar Pharmaceuticals$1.70−36% a year
LFVNLifevantage$0.40−46% a year
Peer median$0.85

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Fulcrum Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.